A study to evaluate serological response and safety to BNT162b2 in patients with Multiple Sclerosis receiving disease-modifying therapies (DMTs)
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 15 Dec 2021 New trial record